This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

AWAK Technologies Enters Into An Exclusive Agreement With Baxter International For The Development Of Wearable Dialysis Technology









SINGAPORE, Jan. 6, 2013 /PRNewswire/ -- AWAK Technologies announced today it has entered into an exclusive agreement with Baxter International, Inc. for the development of innovative wearable dialysis technology.  The agreement enables AWAK to continue the development of its investigational peritoneal dialysis-based automated wearable artificial kidney.  

AWAK Technologies is a research-focused, medical technology company dedicated to the development and commercialization of unique sorbent-based dialysis regeneration technology for wearable and portable dialysis technology used in the treatment of end-stage renal disease (ESRD). The company is a leader in the miniaturization of dialysis technology and their sorbent technology is a key component for dialysate regeneration and it is used in its investigational peritoneal dialysis-based automated wearable artificial kidney.

"As an innovative and technology driven company, we focused on bringing a game-changing technology to meet the needs of dialysis patients around the world," said Dr Gordon Ku, Chairman of AWAK Technologies. "Our agreement with Baxter brings us a step closer to bringing a wearable artificial kidney to market."

The global dialysis industry is projected to reach USD 85 billion in 2015. The number of patients is projected to increase from 3.5 million in 2015 to 4 million by 2020.  Numerous initiatives by government recently, such as out-come based reimbursement and cost reductions, will see migration of patients from existing center-based dialysis to portable and mobile dialysis.

"As a long-recognized global leader in dialysis, Baxter is the right company to help AWAK fulfill its vision of delivering freedom to dialysis patients worldwide and improving their quality of life," said Mr. NEO Kok-Beng, President & CEO of AWAK Technologies. "This agreement will advance our ability to grow and to bring a break-through technology to the marketplace."

"Our agreement with Baxter is part of our overall strategy to bring innovative technologies for dialysis treatment to market that include collaborations and licensing agreements with academia including the University of California, Los Angeles ( UCLA) and Temasek Polytechnic, Singapore as well as working cooperatively with government agencies in the US and Singapore; such as the United States' Veteran Affairs Innovation Initiative (VAi2), SPRING Singapore and International Enterprise (IE) Singapore," Mr. Neo added.

The financial terms for the agreement are not being disclosed, but it will provide Baxter with exclusive global manufacturing and distribution license for AWAK's investigational peritoneal dialysis-based automated wearable artificial kidney, a minority ownership stake in the company and the option to purchase additional equity in the company.

About End Stage Renal Disease and dialysis

The End stage Renal Disease (ESRD) is the fifth stage of Chronic Kidney Disease (CKD) that affects the functioning of kidneys, leading to accumulation of excess fluid and toxic wastes in the blood. People with ESRD undergo either renal transplantation or dialysis. Since renal transplantation is highly dependent on patient's health and age, dialysis scores over as the primary treatment. It was estimated as of 2011, there were 2.7 million ESRD patients of whom 2.1 million were on dialysis. Of these 2.1 million, 10.8% of the patients are on peritoneal dialysis (PD) and the remaining 89.2% are on hemodialysis (HD)[1].

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,566.58 +166.91 1.02%
S&P 500 1,931.99 +27.98 1.47%
NASDAQ 4,389.4430 +73.3690 1.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs